Table 1.
Characteristics of the Salzburg Pancreas cohort 240 patients (2006–2017).
| Characteristic | Score (N = 240) |
|---|---|
| Age—no. of years | |
| Median | 67 |
| Range | 29–90 |
| Sex—no. (%) | |
| Male | 114 (48%) |
| Female | 126 (52%) |
| Tumor stage at diagnosis—no. (%) | |
| Locally advanced | 56 (23.3%) |
| Metastatic | 184 (76.7%) |
| Palliative 1st line protocol—no. (%) | |
| FOLFIRINOX: | 102 (42.5%) |
| Gemcitabine/Nab-Paclitaxel | 31(12.9%) |
| Gemcitabine | 51 (21%) |
| GEMOX | 41 (17%) |
| Other | 15 (6.2%) |
| Chemotherapy beyond 1st line protocol—no. (%) | |
| 2nd line palliative chemotherapy | 138 (57.7%) |
| 3rd line palliative chemotherapy | 66 (27.5%) |
Legend: FOLFIRINOX (5-Fu, oxaliplatin, irinotecan), GEMOX (gemcitabine, oxaliplatin).